The FDA De Novo medical instrument pathway, patents and anticompetition

The interplay between patents and FDA’s De Novo and 510(okay) regulatory pathways has the aptitude to threaten practice-on innovation for medical gadgets. The US Meals and Drug Administration (FDA) has prolonged been criticized — perhaps unfairly — for failing to…